The Diabetes Prevention Program (DPP) randomized 3,234 subjects at high risk of type 2 diabetes (T2D) to one of three arms: placebo, metformin 850 mg twice daily or an intensive lifestyle intervention (a fourth arm of 585 subjects assigned to troglitazone treatment was stopped prematurely because of one incident of fatal hepatotoxicity). Over a 4-year period, close to 40% of subjects in the placebo group developed T2D;there was a significant reduction in the incidence of T2D among both the metformin and the lifestyle intervention groups. We propose to explore whether common genetic variation at a number of candidate genes might help predict progression to T2D or response to any of the above interventions. We have selected up to 66 genes which have been implicated in glucose homeostasis. These include genes that cause monogenic forms of T2D or obesity, genes that encode targets of hypoglycemic medications, genes involved in cellular energy regulation (including the mitochondrial genome), genes that participate in metabolic endocrine networks and genes affected by the human response to exercise. The haplotype structure of all of the above genes will be fully characterized with the aid of the data provided by the HapMap Project, complemented by our own genotyping and sequencing efforts. Haplotype tag single nucleotide polymorphisms will be genotyped in the DPP cohort. The impact of a specific allelic variant on the development of T2D will be assessed in each of the intervention arms. Secondary endpoints will include measures of insulin secretion and insulin resistance based on the initial and final oral glucose tolerance test. If successful, the proposed research should help elucidate the genetic heterogeneity of T2D and obesity, as well as lay the foundation for pharmacogenetic studies of treatment response and prevention in T2D.
| Kim, Catherine; Aroda, Vanita R; Goldberg, Ronald B et al. (2018) Androgens, Irregular Menses, and Risk of Diabetes and Coronary Artery Calcification in the Diabetes Prevention Program. J Clin Endocrinol Metab 103:486-496 |
| Fitipaldi, Hugo; McCarthy, Mark I; Florez, Jose C et al. (2018) A Global Overview of Precision Medicine in Type 2 Diabetes. Diabetes 67:1911-1922 |
| Mercader, Josep M; Liao, Rachel G; Bell, Avery D et al. (2017) A Loss-of-Function Splice Acceptor Variant in IGF2 Is Protective for Type 2 Diabetes. Diabetes 66:2903-2914 |
| Florez, Jose C (2017) Mining the Genome for Therapeutic Targets. Diabetes 66:1770-1778 |
| Florez, Jose C (2017) The pharmacogenetics of metformin. Diabetologia 60:1648-1655 |
| Florez, Jose C (2017) Pharmacogenetics in type 2 diabetes: precision medicine or discovery tool? Diabetologia 60:800-807 |
| Kim, Catherine; Dabelea, Dana; Kalyani, Rita R et al. (2017) Changes in Visceral Adiposity, Subcutaneous Adiposity, and Sex Hormones in the Diabetes Prevention Program. J Clin Endocrinol Metab 102:3381-3389 |
| McCaffery, Jeanne M; Jablonski, Kathleen A; Franks, Paul W et al. (2017) Replication of the Association of BDNF and MC4R Variants With Dietary Intake in the Diabetes Prevention Program. Psychosom Med 79:224-233 |
| Ferreira, Leonardo M R; Meissner, Torsten B; Mikkelsen, Tarjei S et al. (2016) A distant trophoblast-specific enhancer controls HLA-G expression at the maternal-fetal interface. Proc Natl Acad Sci U S A 113:5364-9 |
| Hall, Kathryn T; Jablonski, Kathleen A; Chen, Ling et al. (2016) Catechol-O-methyltransferase association with hemoglobin A1c. Metabolism 65:961-967 |
Showing the most recent 10 out of 50 publications
